Gilead Sciences, Inc. (GILD) vs Eli Lilly and Company (LLY)
- Gilead Sciences, Inc. GILD 156.19 −0.75%
- Eli Lilly and Company LLY 1,257.03 +0.43%
Gilead Sciences, Inc. and Eli Lilly and Company are both Drug Manufacturers General companies. Eli Lilly and Company is the larger, with a market value of $1.18T against $195.1B — 6.0× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Eli Lilly and Company trades at 42.2×. Eli Lilly and Company grew revenue faster over the last twelve months: 49.6% against 5.52%. Eli Lilly and Company has the higher net margin (33.5% vs −10.6%) and the higher return on invested capital (26.3% vs −4.48%). Both pay a dividend; Gilead Sciences, Inc. yields more (2.08% vs 0.53%). Across the 22 metrics below, Eli Lilly and Company leads on 13 and Gilead Sciences, Inc. on 9.
Valuation
Profitability
| Metric | GILD | LLY | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 79.59% | 83.40% | 72.77% |
| Operating margin | (8.20%) | 42.22% | 18.77% |
| Net margin | (10.64%) | 33.53% | 8.27% |
| Free cash flow margin | 42.50% | 22.83% | 17.18% |
| Return on equity | (20.68%) | 102.29% | 5.87% |
| Return on assets | (6.17%) | 21.97% | 2.57% |
| Return on invested capital | (4.48%) | 26.33% | 6.11% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack